share_log

Baird Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $65

Benzinga ·  Oct 30 06:28  · Ratings

Baird analyst Joel Beatty maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $72 to $65.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment